Since August, 2005, this news digest has been a complimentary service of GBP Capital, a private equity firm investing in early to mid-stage life science companies. See www.gbpcap.com. The digest is published two to four days a week. If you have colleagues who would be interested in receiving this digest by email, they can be added to the list at: http://www.gbpcap.com/. Also, the complete history of the entire content of all news articles in our digests since August, 2005 is searchable with Google's enterprise search engine at the same site.
Journal of Biological ChemistrySignificant findings about protein architecture may aid in drug design, generation of nanomaterials
Researchers in Singapore are reporting this week that they have gleaned key insights into the architecture of a protein that controls iron levels in almost all organisms. Their study culminated in one of the first successful attempts to take apart a complex biological nanostructure and isolate the rules that govern its natural formation.
Singapore Ministry of Education, Nanyang Technological UniversityContact: Angela Hopp
ahopp@asbmb.org
301-634-7389
American Society for Biochemistry and Molecular Biology
Public Release: 9-Apr-2010
Metabolic fingerprints offer fresh clues and a new path toward personalized medicine
Human metabolism proves to be as variable and individual as people's appearance or build -- despite nearly identical genetic inheritance. Better understanding of the differences could, for example, lead to more effective screening and treatment for diabetes and cardiovascular disease. Pioneering "metabolomics" as a path toward personalized medicine and nutrition, Munich area researchers have harnessed capabilities ranging from NMR and mass spectrometry to bioinformatics, all within a framework for conducting human studies.
Contact: Jana Bodicky
bodicky@zv.tum.de
49-816-171-5403
Technische Universitaet Muenchen
Public Release: 8-Apr-2010 Science
Cancer drug effectiveness substantially advanced
Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.
Contact: Josh Baxt
jbaxt@sanfordburnham.org
858-795-5236
Sanford-Burnham Medical Research Institute
Public Release: 8-Apr-2010 Immunity
Researchers use novel nanoparticle vaccine to cure type 1 diabetes in mice
Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases. Juvenile Diabetes Research Foundation
Public Release: 8-Apr-2010 Journal of the American Chemical Society
New method to study key targets in Alzheimer's disease and prostate cancer
When designing a drug against a disease, chemists often used detailed plans of the proteins affected and against which the drugs must act. However, about a third of the proteins of our bodies have not yet been "photographed" because they generally vary in form, are in constant movements and have very little structure.
Contact: Sònia Armengou
sonia.armengou@irbbarcelona.org
34-934-037-255
Institute for Research in Biomedicine (IRB Barcelona)
Source - Science Daily :
Please note : Due to the format restrictions of Science Daily articles, you must click on the URL (web address) below the article summary , rather than the article title.
April 9, 2010 — Using adult stem cells, researchers have created functional blood vessels that could one day replace synthetic grafts often required in various vascular bypass surgeries, according to new ...
http://www.sciencedaily.com/releases/2010/04/100408181653.htm
New Way HIV Infects Women Discovered
April 9, 2010 — Scientists have been puzzled as to how HIV finds its way into the female reproductive tract. The culprit could be HIV itself and what the virus does when it binds to epithelial ...
http://www.sciencedaily.com/releases/2010/04/100408171506.htm
Perioperative Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
April 9, 2010 — A research team from China performed a randomized controlled study to evaluate the outcome of preoperative and postoperative chemoradiotherapy (CRT) in patients with local advanced thoracic ...
http://www.sciencedaily.com/releases/2010/04/100409093217.htm
Leukemia-Related Protein 16 and Colorectal Carcinoma
April 9, 2010 — A research team from China investigated the expression of leukemia-related protein 16 (LRP16) in colorectal cancer and normal mucosas and possible relationship between LRP16 expression and ...
http://www.sciencedaily.com/releases/2010/04/100409093215.htm
Novel Nanoparticle Vaccine Cures Type 1 Diabetes in Mice
April 8, 2010 — Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study ...
http://www.sciencedaily.com/releases/2010/04/100408121054.htm
New Method to Study Key Targets in Alzheimer's Disease and Prostate Cancer
April 8, 2010 — When designing a drug against a disease, chemists often used detailed plans of the proteins affected and against which the drugs must act. However, about a third of the proteins of our bodies have ...
http://www.sciencedaily.com/releases/2010/04/100408105202.htm
Powerful New Method Allows Scientists to Probe Gene Activation
April 8, 2010 — Researchers have developed a powerful new method to investigate the discrete steps necessary to turn on individual genes and examine how the process goes wrong in cancer and other diseases. The ...
http://www.sciencedaily.com/releases/2010/04/100408121058.htm
- Xenon Gas May Protect Brain
- St. John's Wort Not Effective for Anxiety: Doctor
- EPA Introduces New Lead Safety Regulation
- Gene Fault Linked to Deafness: Study
Scientists Grow Replacement Blood Vessels From Stem Cells
These grafts worked well in animals, but testing in humans is still a few years off
Clinical Trials Update: April 9, 2010
- ADHD Sleep
- Social Anxiety Disorder
- Type 2 Diabetes
CTI Receives Complete Response Letter from the FDA for Pixantrone NDA; CTI to File for Expanded Access for Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma - PR Newswire - Fri 1:15 am ET
Cell Therapeutics, Inc. today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for Pixuvri™ for relapsed or refractory aggressive non-Hodgkin's lymphoma . The FDA cited as its primary reason for the action its concerns previously raised at the Oncologic Drugs Advisory Committee meeting on March 22, 2010 and recommended the Company conduct an additional trial to demonstrate the safety and effectiveness of its product. Based on the FDA's ODAC presentation, which provided the Committee and the Company with alternative options to consider to make investigational drugs available to patients if drugs need to be studied further prior to approval, the Company has decided to pursue expanded access program for pixantrone while it conducts an additional study in aggressive NHL.
First Patients Enrolled in Cordis Trial of New Stent Graft System to Treat Abdominal Aortic Aneurysm - Business Wire - Fri 7:32 am ET
BRIDGEWATER, N.J.----Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technologies, announced today that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of a new stent graft system, called INCRAFT™, to treat abdominal aortic aneurysm .
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Refractory Advanced Colorectal Cancer - PR Newswire - Thu 8:30 am ET
Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 , the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, for the treatment of patients with refractory advanced colorectal cancer.
Gene therapy `can make the blind see`
Contactlenses.co.uk
By Adrian Galbreth A radical new type of gene therapy may be able to make visually-impaired people see clearly again, according to experts in the US, ...
Britain Slashes Swine Flu Vaccine Order
BusinessWeek
GSK said that the Government would receive other treatments, such as H5N1 bird flu vaccine and courses of the anti-viral Relenza, to balance the deal. ...
As overall cancer rates are declining in the United States, thyroid cancer counters the trend. It's being diagnosed more frequently, especially in women. Women are three times more likely than men to develop thyroid cancer. The April issue of Mayo Clinic Women's HealthSource provides an overview of thyroid cancer, what may be behind some of the increasing numbers, and warning signs of the disease.
http://www.medicalnewstoday.com/articles/184992.php
Biomarker Could Be World's First Reliable Test For Liver Cancer
Liver cancer is the fifth most common cancer in the world and one of the deadliest cancers since it is rarely diagnosed until late in its development. The lack of reliable screening tests for liver cancer contributes to its high mortality rate since tumors seldom cause symptoms until the later stages when treatment options become limited and the prognosis is poorer. Death usually occurs not long after diagnosis.
http://www.medicalnewstoday.com/articles/185013.php
CureDM Partners Novel Diabetes Treatment With Sanofi-Aventis
CureDM, LLC announced today that an agreement has been signed with Sanofi-Aventis (EURONEXT: SAN and NYSE: SNY) for the exclusive worldwide license of Pancreate™, a novel islet neogenesis agent for the treatment of type 1 and type 2 diabetes. CureDM is a privately held biopharmaceutical company whose scientists discovered Pancreate™, a first-in-class human peptide therapeutic. Several key Composition of Matter and Use patents have been issued to CureDM for this potentially transforming treatment approach for diabetes.
http://www.medicalnewstoday.com/articles/185008.php
Cancer Drug Effectiveness Substantially Advanced
Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug. In a transformative paper published in the online edition of the journal Science, Erkki Ruoslahti, M.D., Ph.D., distinguished professor at Sanford-Burnham Medical Research Institute and founding member of the UC Santa Barbara-Sanford|Burnham Center for Nanomedicine, Kazuki N. Sugahara, M.D., Ph.D., Tambet Teesalu, Ph.D., and fellow researchers at the Center for Nanomedicine and the Cancer Center of Santa Barbara, announced this significant advance in cancer therapy.
http://www.medicalnewstoday.com/articles/184883.php
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.